Journal article
Anti-Angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
T Mele, D Generali, S Fox, MP Brizzi, A Bersiga, M Milani, G Allevi, S Bonardi, S Aguggini, M Volante, L Dogliotti, A Bottini, A Harris, A Berruti
Breast Cancer Research and Treatment | SPRINGER | Published : 2010
Abstract
Vascular endothelial growth factor A (VEGFA) and vascular endothelial growth factor receptor 2 (VEGFR2) are the key factors mediating neo-vascularization. They are often coexpressed in breast cancer. Sex steroids may stimulate angiogenesis via the estrogen receptor (ER) pathway. We investigated to compare the effects of the addition of tamoxifen to epirubicin versus epirubicin alone on VEGF and VEGFR2 expression in breast cancer patients. The expression of VEGF and VEGFR2 was assessed on tissue microarray by immunohistochemistry at baseline conditions and after treatments in the case of 191 patients with T2-4 N0-1 breast cancer enrolled in a randomized trial comparing four cycles of single a..
View full abstractGrants
Funding Acknowledgements
This work was supported in part by the 'Associazione Patologia Oncologica Mammaria - APOM', Cremona, Italy, by the Association of 'Amici dell'Ospedale di Cremona', by Cancer Research UK (CRUK), UK and the Oxford NIHR Biomedical Research Programme.